



Express Mail Label No.: EV 533193418 US

Sheet 1 of 2

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:  
OC01617K1

APPLICATION NO.:  
10/776, 988

APPLICANT:  
Timothy J. Guzi et al.

FILING DATE:  
02/11/2004

GROUP:

16 L 2

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
TY	AA 5,571,813	11/05/1996	Rühter et al.	/	/	
	AB 5,602,136	02/11/1997	Rühter et al.			
	AC 5,602,137	02/11/1997	Rühter et al.			
	AD 5,688,949	11/18/1997	Inoue et al.			
	AE 5,707,997	01/13/1998	Shoji et al.			
	AF 5,919,815	07/06/1999	Bradley et al.			
	AG 6,040,321	03/21/2000	Kim et al.			
	AH 6,107,305	08/22/2000	Misra et al.			
	AI 6,191,131	02/20/2001	He et al.			
	AJ 6,262,096	07/17/2001	Kim et al.			
	AK 6,413,974	07/02/2002	Dumont et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO
✓	AL DE 102 23 917 A1	11/12/2003	Germany				
	AM EP 0 628 559	04/03/2002	Europe				
	AN EP 1 334 973	08/13/2003	Europe				
	AO WO 02/22610	03/21/2002	PCT				
	AP WO 02/40485	05/23/2002	PCT				
	AQ WO 02/50079	06/27/2002	PCT				
✓	AR WO 03/091256 A1	11/06/2003	PCT				
	AS WO 95/35298	12/28/1995	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	AT	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-786.
	AU	Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>Journal of Medical Chemistry</i> , (2002), 45: 3905-3927.
	AV	Meltey et al., "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects", <i>J. Med. Chem.</i> (2003), 46(2): 222-236.
	AW	Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-a]pyrimidines", <i>J. Med. Chem.</i> (1977), 20(2): 298-299.
	AX	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.
✓	AY	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243:527-536.

EXAMINER

*Tom McCabe*

DATE CONSIDERED

*6/17/07*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.: <u>OC01617K1</u>	APPLICATION NO.: <u>10/776,988</u>
		APPLICANT: <u>Timothy J. Guzi et al.</u>	
		FILING DATE: <u>02/22/2004</u>	GROUP: <u>67</u>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
AZ	Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), <b>57</b> : 3375-3380.		
BA	Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-a]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), <b>47</b> (7): 928-938.		
BB	Translation of WO 03/91256, <i>A Rising Sun Communications Ltd. Translation Product</i> , (1-62)		
BC	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-a]pyrimidines.", <i>Chem. Pharm. Bull.</i> (1962), <b>10</b> : 620-626.		
BD	Cai et al., "5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors", <i>J. Med. Chem.</i> (1997), <b>40</b> :3679-3686.		
BE	Bruce L. Finkelstein, "Regioselective Lithiation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and Pyrazolo[1,5-a]pyridine", <i>J. Org. Chem.</i> , (1992), <b>57</b> : 5538-5540.		
BF	Ongkeko et al., "Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage", <i>Journal of Cell Science</i> (1995), <b>108</b> : 2897-2904.		
BG	Shiota et al., "Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and 5,7-Dichloropyrazolo[1,5-a]pyrimidine", <i>J. Org. Chem.</i> (1999), <b>64</b> : 453-457.		
BH	Novinson et al., "Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-a-s-triazines", <i>Journal of Medicinal Chemistry</i> , (1976), <b>19</b> (4): 517-520.		
BI			
EXAMINER <i>Don Miley</i>	DATE CONSIDERED <u>6/17/04</u>		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			